CJC-1295 DAC vs GHRP-2
A side-by-side research comparison of CJC-1295 DAC and GHRP-2 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 DAC | GHRP-2 |
|---|---|---|
| Full name | CJC-1295 with Drug Affinity Complex | Growth Hormone Releasing Peptide-2 (Pralmorelin) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | The DAC moiety binds serum albumin creating a depot that slowly releases active CJC-1295 for continuous GHRH signaling. | Potent GHSR-1a agonist stimulating GH release and appetite. Also mildly stimulates ACTH/cortisol release. |
| Molecular weight | 3,647 Da | 818 Da |
| Half-life | 8 days | 1-2 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 2 mg | 100-300 mcg |
| Frequency | 1-2x per week | 2-3x daily |
| Route | Subcutaneous | Subcutaneous |
CJC-1295 DAC reported benefits
- Once/twice weekly dosing
- Sustained IGF-1 elevation
- Convenient schedule
- Long-term body composition changes
GHRP-2 reported benefits
- Strongest GH release among GHRPs
- Appetite stimulation
- Recovery improvement
- Enhanced sleep
- Muscle preservation
Related comparisons
Research and educational reference only. Not medical advice.